拓扑异构酶
抄写(语言学)
化学
癌症研究
DNA
DNA损伤
细胞周期蛋白依赖激酶7
RNA聚合酶Ⅱ
激酶
DNA修复
细胞生物学
聚合酶
结合
转录因子
核糖核酸
生物
拓扑异构酶抑制剂
分子生物学
细胞周期
酶
合成致死
支票1
DNA聚合酶
癌细胞
后天抵抗
同源重组
生物化学
DNA损伤修复
细胞周期检查点
癌症
延伸系数
作者
Hyerim Jung,Yoonji Lee,DongHoon Yu,Yeejin Jeon,Hwankyu Kang,Dahun Um,Mooyoung Seo,Dongsik Park,Jeongjun Kim,Seung-Joo Lee,Jaeseung Kim,Lauren Escobedo,Yilun Sun,Anish Thomas,Kiyean Nam,Tae-Kyung Kim
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2026-09-30
卷期号:12 (40): eaeb4023-eaeb4023
被引量:1
标识
DOI:10.1126/sciadv.aeb4023
摘要
This study investigates the transcriptional impact of Q901, a highly selective cyclin-dependent kinase 7 (CDK7) inhibitor in clinical development. Q901 primarily disrupted MYC and E2F-dependent transcription programs, down-regulating cell cycle control and DNA damage repair pathways. CDK7 binding at the promoter-proximal regions was markedly stabilized by Q901, leading to reduced occupancy of MYC, E2F, and RNA polymerase II (RNAPII). These findings offered a novel therapeutic strategy to enhance cancer susceptibility to topoisomerase I (TOP1) DNA-protein cross-links (TOP1-DPCs) induced by TOP1 inhibitors. Resistance to TOP1 inhibitors arises through activation of DNA repair pathways when elongating RNAPII encounters TOP1-DPCs. By suppressing RNAPII transition from initiation to elongation and DNA repair pathways, Q901 stabilizes TOP1-DPCs and sensitizes tumors to TOP1 inhibitors. Preclinical studies demonstrated enhanced tumor suppression when combining Q901 with TOP1 inhibitor-based antibody-drug conjugates (TOP1i-ADCs), highlighting its potential as a therapeutic option for cancers resistant to TOP1i-ADC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI